Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
A study to determine the feasibility and safety of individualized cancer stem cell targeted
therapy based on high-throughput functional profiling of FDA/EMA-approved drugs in patients
with GBM that has recurred or progressed following standards-of-care (RT, TMZ).